X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
0
Europe
Canada
0
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
Details:
Jalra-Trio (vildagliptin + dapagliflozin + metformin) is a fixed dose combination medicine that helps control blood sugar levels. It is now approved for the treatment of type-2-diabetes mellitus.
Lead Product(s): Vildagliptin,Dapagliflozin,Metformin
Therapeutic Area: Endocrinology Product Name: Jalra Trio
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 11, 2023
Details:
Pioz V (vildagliptin + pioglitazone) is a fixed dose combination medicine that helps control blood sugar levels. It is now approved for the treatment of type-2-diabetes mellitus.
Lead Product(s): Vildagliptin,Pioglitazone
Therapeutic Area: Endocrinology Product Name: Pioz V
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2023
Details:
Under the terms of the agreement, Cipla will manufacture and market Galvus (vildagliptin) and Galvus combination brands, used in the treatment of type 2 diabetes.
Lead Product(s): Vildagliptin
Therapeutic Area: Endocrinology Product Name: Galvus
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cipla
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 11, 2023
Details:
Glenmark is the first company in the world to launch Remogliflozin + Vildagliptin + Metformin fixed dose combination (FDC) and India is the first country to get access to this FDC drug.
Lead Product(s): Remogliflozin Etabonate,Vildagliptin,Metformin
Therapeutic Area: Endocrinology Product Name: Remozen MV
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2021
Details:
Under the agreement, USV acquires the trademark for antidiabetes drug Jalra (vildagliptin) and Jalra M (vildagliptin and metformin), used to treat type 2 diabetes mellitus, from Novartis.
Lead Product(s): Vildagliptin
Therapeutic Area: Endocrinology Product Name: Jalra
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: USV Private Limited
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 22, 2021
Details:
Glenmark is the first company in the world to launch Remogliflozin (100 mg) + Vildagliptin (50 mg) Fixed Dose Combination. The FDC will be marketed under two brand names Remo V and Remozen V.
Lead Product(s): Remogliflozin Etabonate,Vildagliptin
Therapeutic Area: Endocrinology Product Name: Remozen V
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 29, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
USV offers custom peptide synthesis ranging from gram to multi-gram to multi-kilogram quantities.
